GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2007

Health Discovery Files Patent for Prostate Cancer Biomarker Discovery

  • Health Discovery (HDC) filed a patent for U.S. and foreign protection for a newly discovered prostate cancer biomarker expression signature. "This new and exciting biomarker discovery could play a significant role in a more accurate diagnosis of prostate cancer as well as could provide important information for the development of new drug targets for the successful treatment of prostate cancer," comments Herbert A. Fritsche, Ph.D., professor of laboratory medicine at the University of Texas M.D. Anderson Cancer Center and chairman of HDC's science team.

    "As medicine becomes increasingly personalized, discoveries of this nature could facilitate the development of new diagnostic tests and innovative treatments for prostate cancer," adds Dr. Fritsche.

    According to a recent paper published in the Journal of Urology by Tom Stamey, M.D., at Stanford University Medical Center and a member of HDC’s science team, the era of prostate specific antigen (PSA) is over because of its low accuracy rate in identifying clinically significant prostate cancer. Dr. Stamey believes that a more accurate test is needed to effectively detect this type of cancer.

    "I firmly believe that this new prostate cancer biomarker discovery provides a significant opportunity towards providing a more accurate diagnosis of prostate cancer and important new information for identifying new therapeutic targets in treating this potentially devastating type of cancer," states Stephen D. Barnhill, M.D., chairman & CEO.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?